|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DCLK1 |
Gene summary for DCLK1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DCLK1 | Gene ID | 9201 |
| Gene name | doublecortin like kinase 1 | |
| Gene Alias | CL1 | |
| Cytomap | 13q13.3 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | O15075 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9201 | DCLK1 | RNA-P17T-P17T-2 | Human | Lung | IAC | 3.19e-06 | 8.99e-01 | 0.3371 |
| 9201 | DCLK1 | RNA-P17T-P17T-4 | Human | Lung | IAC | 1.06e-06 | 8.17e-01 | 0.343 |
| 9201 | DCLK1 | RNA-P17T-P17T-6 | Human | Lung | IAC | 5.58e-10 | 1.10e+00 | 0.3385 |
| 9201 | DCLK1 | RNA-P17T-P17T-8 | Human | Lung | IAC | 5.66e-03 | 6.54e-01 | 0.3329 |
| 9201 | DCLK1 | EOLP-1 | Human | Oral cavity | EOLP | 5.49e-04 | 1.82e-01 | -0.0202 |
| 9201 | DCLK1 | EOLP-2 | Human | Oral cavity | EOLP | 3.08e-04 | 1.75e-01 | -0.0203 |
| 9201 | DCLK1 | NEOLP-1 | Human | Oral cavity | NEOLP | 2.29e-33 | 9.88e-01 | -0.0194 |
| 9201 | DCLK1 | NEOLP-2 | Human | Oral cavity | NEOLP | 4.61e-15 | 5.27e-01 | -0.0196 |
| 9201 | DCLK1 | NEOLP-3 | Human | Oral cavity | NEOLP | 6.47e-10 | 3.57e-01 | -0.0191 |
| 9201 | DCLK1 | ATC13 | Human | Thyroid | ATC | 1.55e-28 | 5.88e-01 | 0.34 |
| 9201 | DCLK1 | ATC4 | Human | Thyroid | ATC | 2.81e-02 | 1.23e-01 | 0.34 |
| 9201 | DCLK1 | ATC5 | Human | Thyroid | ATC | 9.98e-30 | 6.44e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00181056 | Lung | IAC | peptidyl-serine phosphorylation | 69/2061 | 315/18723 | 1.48e-08 | 1.87e-06 | 69 |
| GO:00182095 | Lung | IAC | peptidyl-serine modification | 70/2061 | 338/18723 | 1.23e-07 | 1.10e-05 | 70 |
| GO:00163586 | Lung | IAC | dendrite development | 55/2061 | 243/18723 | 1.35e-07 | 1.18e-05 | 55 |
| GO:00605605 | Lung | IAC | developmental growth involved in morphogenesis | 52/2061 | 234/18723 | 5.39e-07 | 3.32e-05 | 52 |
| GO:00160496 | Lung | IAC | cell growth | 89/2061 | 482/18723 | 6.10e-07 | 3.67e-05 | 89 |
| GO:00485885 | Lung | IAC | developmental cell growth | 49/2061 | 234/18723 | 6.67e-06 | 2.43e-04 | 49 |
| GO:00488134 | Lung | IAC | dendrite morphogenesis | 34/2061 | 146/18723 | 1.68e-05 | 4.79e-04 | 34 |
| GO:00486755 | Lung | IAC | axon extension | 29/2061 | 120/18723 | 3.29e-05 | 8.29e-04 | 29 |
| GO:19901384 | Lung | IAC | neuron projection extension | 37/2061 | 172/18723 | 4.69e-05 | 1.08e-03 | 37 |
| GO:00615646 | Lung | IAC | axon development | 78/2061 | 467/18723 | 1.12e-04 | 2.15e-03 | 78 |
| GO:00074096 | Lung | IAC | axonogenesis | 71/2061 | 418/18723 | 1.33e-04 | 2.48e-03 | 71 |
| GO:00161976 | Lung | IAC | endosomal transport | 43/2061 | 230/18723 | 3.53e-04 | 5.50e-03 | 43 |
| GO:00096156 | Lung | IAC | response to virus | 61/2061 | 367/18723 | 6.75e-04 | 9.12e-03 | 61 |
| GO:0001764 | Lung | IAC | neuron migration | 31/2061 | 156/18723 | 7.89e-04 | 1.02e-02 | 31 |
| GO:00345047 | Lung | IAC | protein localization to nucleus | 50/2061 | 290/18723 | 8.71e-04 | 1.11e-02 | 50 |
| GO:00219552 | Lung | IAC | central nervous system neuron axonogenesis | 11/2061 | 35/18723 | 9.48e-04 | 1.15e-02 | 11 |
| GO:00309002 | Lung | IAC | forebrain development | 61/2061 | 379/18723 | 1.52e-03 | 1.61e-02 | 61 |
| GO:0021954 | Lung | IAC | central nervous system neuron development | 18/2061 | 81/18723 | 2.68e-03 | 2.46e-02 | 18 |
| GO:001810514 | Oral cavity | EOLP | peptidyl-serine phosphorylation | 84/2218 | 315/18723 | 3.32e-13 | 1.05e-10 | 84 |
| GO:001820914 | Oral cavity | EOLP | peptidyl-serine modification | 87/2218 | 338/18723 | 1.07e-12 | 2.46e-10 | 87 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DCLK1 | SNV | Missense_Mutation | novel | c.1243N>A | p.Glu415Lys | p.E415K | O15075 | protein_coding | tolerated(0.1) | benign(0.34) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DCLK1 | SNV | Missense_Mutation | novel | c.1162G>C | p.Glu388Gln | p.E388Q | O15075 | protein_coding | tolerated(0.21) | benign(0.059) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DCLK1 | SNV | Missense_Mutation | c.2125N>A | p.Tyr709Asn | p.Y709N | O15075 | protein_coding | tolerated_low_confidence(0.3) | benign(0.005) | TCGA-E2-A1AZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| DCLK1 | SNV | Missense_Mutation | c.178C>T | p.Arg60Cys | p.R60C | O15075 | protein_coding | deleterious(0.02) | benign(0.151) | TCGA-E2-A1B0-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| DCLK1 | SNV | Missense_Mutation | c.913N>G | p.Ser305Gly | p.S305G | O15075 | protein_coding | tolerated(0.14) | possibly_damaging(0.496) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD | |
| DCLK1 | insertion | Frame_Shift_Ins | novel | c.531_532insCTCTTGGG | p.Glu178LeufsTer21 | p.E178Lfs*21 | O15075 | protein_coding | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | ||
| DCLK1 | insertion | Nonsense_Mutation | novel | c.529_530insTAATTCTAATCTGAAGTAAAAATAATTTGGTC | p.Arg177LeufsTer5 | p.R177Lfs*5 | O15075 | protein_coding | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | ||
| DCLK1 | SNV | Missense_Mutation | rs769128085 | c.989C>T | p.Ser330Leu | p.S330L | O15075 | protein_coding | deleterious(0.02) | possibly_damaging(0.747) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| DCLK1 | SNV | Missense_Mutation | novel | c.194N>C | p.Gly65Ala | p.G65A | O15075 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-VS-A950-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| DCLK1 | SNV | Missense_Mutation | novel | c.1103A>C | p.Asn368Thr | p.N368T | O15075 | protein_coding | tolerated(0.58) | benign(0.006) | TCGA-VS-A9V4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 9201 | DCLK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | TAE-684 | TAE-684 | ||
| 9201 | DCLK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | CENISERTIB | CENISERTIB | ||
| 9201 | DCLK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 249565887 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |